Business
Neuronetics Announces Data Confirming Efficacy in Treating Anxious Depression with NeuroStar® Advanced Therapy for Mental Health
Peer-reviewed publication shows NeuroStar TMS as an effective non-drug treatment for depression with comorbid anxiety MALVERN, Pa., Jan. 17, 2023 (GLOBE
About this update from Neuronetics, Inc.
[{"type":"text","content":"Peer-reviewed publication shows NeuroStar TMS as an effective non-drug treatment for depression with comorbid anxiety\nMALVERN, Pa., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced a new peer-reviewed publication in the Journal of Clinical Psychiatry, presenting real-world evidence of the efficacy of NeuroStar Advanced Therapy for adult patients who suffer concurrently from anxiety symptoms and major depressive disorder (MDD), also known as anxious depression. “Not only is NeuroStar proven to effectively treat people with MDD, but it is also proven to specifically help people suffering from anxiety with depression,” stated Keith J. Sullivan, President, and CEO of Neuronetics Inc. “The great majority of depressed patients experience significant anxiety symptoms, and comorbid depression is found in most patients with anxiety disorders. The power of our proprietary TrakStar® platform, coupled with the largest clinical data set for TMS in depression, allowed us to examine real-world outcomes and document the efficacy of this important treatment option for patients suffering from anxious depression.” Using data from the world’s largest depression outcomes registry of more than 15,000 patients, the publication authors analyzed a sample of over 1,800 patients. These 1,800 patients were treated with NeuroStar TMS in commercial clinics and represented a diversity of patients with MDD and moderate-to-severe anxiety symptoms. Patients with anxious depression exhibited clinically meaningful anxiety symptom improvement and antidepressant effects. These results represent large treatment effect sizes (Cohen’s d) of 1.47 on the GAD-7 and 1.74 on the PHQ-9 after receiving NeuroStar TMS treatment. The findings of this study also showed that the magnitude of improvement in depressive symptoms did not differ based on baseline patient anxiety severity, with all groups experiencing robust and nearly equivalent antidepressant effects. “In my years of psychiatric practice, I have seen many depressed patients experiencing significant anxiety symptoms that can be debilitating,” said Dr. Todd Hutton, M.D., Chief Medical Director at Sou...